DJIA52065.38 -315.28
S&P 5007603.30 -33.06
NASDAQ26116.64 -136.70
Russell 20002898.93 -22.30
German DAX25401.23 -175.22
FTSE 10010609.99 -60.07
CAC 408116.76 -39.91
EuroStoxx 506269.65 -42.10
Nikkei 22565270.95 128.17
Hang Seng24954.47 -320.49
Shanghai Comp3934.40 -17.11
KOSPI7033.92 -17.72
Bloomberg Comm IDX146.29 1.15
WTI Crude-fut102.15 4.30
Brent Crude-fut101.52 4.44
Natural Gas2.80 0.00
Gasoline-fut3.36 0.14
Gold-fut4409.00 -37.00
Silver-fut64.86 -3.06
Platinum-fut1809.70 -94.70
Palladium-fut1303.50 -66.50
Copper-fut6.54 -0.32
Aluminum-spot3195.00 0.00
Coffee-fut290.75 -0.40
Soybeans-fut1327.75 19.00
Wheat-fut734.25 5.50
Bitcoin76898.84 -1098.68
Ethereum USD2438.45 -14.51
Litecoin51.96 -0.94
Dogecoin0.08 -0.01
EUR/USD1.1624 0.0003
USD/JPY153.52 -0.56
GBP/USD1.3535 -0.0001
USD/CHF0.8106 0.0009
USD IDX98.91 0.16
US 10-Yr TR4.926 0.086
GER 10-Yr TR3.506 0.0097
UK 10-Yr TR5.3854 0.0076
JAP 10-Yr TR2.91 0
Fed Funds3.75 0
SOFR3.64 0
High-rise commercial buildings

Sub Markets

Topics

Direct Investment  + Alternative Assets  + Latest News  + M&As  + Private Equity  | 
Elliot, Patient Square, Veritas to Take Syneos Health Private for $7B+

Elliott, Patient Square, Veritas to Take Syneos Health Private for $7B+

A consortium of private equity investors, including Elliott Investment Management, Patient Square Capital and Veritas Capital, agreed to take Syneos Health, a contract research organization, private for $7.1 billion, including nearly $3 billion in debt.

The group will pay $43 a share in cash for the North Carolina-based company, representing a 24% premium to its closing price on February 13, 2023. The transaction is expected to close in the second half of 2023.

“We believe this transaction will enable Syneos Health to continue to accelerate its growth strategy, enhance customer delivery and evolve the organization toward a tech-enabled future,” said John Dineen, Chair of the Syneos Health Board of Directors.

Over the years, private ownership of contract research companies has changed. The industry has been viewed to wager on the sector’s overall growth without the volatility risk of investing in particular medications or tiny biotechs because of its recurrent revenues and collaboration with the biotech and pharmaceutical industries.

Syneos was established in 2017, when INC Research Holdings acquired inVentiv Health for $7.4 billion, including debt. To work with Microsoft Research and take advantage of advancements made by OpenAI, Syneos and Microsoft struck a strategic multi-year deal earlier this year.

Connect

Inside The Story

Syneos Health

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.